Security
Acrivon Therapeutics, Inc. Common Stock · ACRV
ACRVNASDAQCommon stockCurrentCIK 1781174Updated Nov 20, 2026
ACRV price & chart
Loading TradingView…
NASDAQ:ACRV on TradingView ↗About the company
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.
In the news
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
S-3 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Other Events
Items 8.01, 9.01
4 filing
144 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 145,299,000Source | 214,684,000Source | 99,092,000Source | 158,583,000Source | 230,585,000Source | 107,832,000Source | 176,349,000Source | 120,521,000Source | 129,717,000Source | 196,588,000Source | 138,265,000Source | 181,226,000Source |
| Property, Plant and Equipment, NetUSD | 5,189,000Source | 4,670,000Source | 4,248,000Source | 5,072,000Source | 3,467,000Source | 4,653,000Source | 4,676,000Source | 3,408,000Source | 4,889,000Source | 4,471,000Source | 3,479,000Source | 2,092,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 35,405,000Source | 43,415,000Source | 41,417,000Source | 41,895,000Source | 46,006,000Source | 34,064,000Source | 39,154,000Source | 24,607,000Source | 41,499,000Source | 39,818,000Source | 36,015,000Source | 29,519,000Source |
| Assets, CurrentUSD | 130,361,000Source | 188,984,000Source | 91,493,000Source | 138,412,000Source | 182,358,000Source | 99,220,000Source | 151,327,000Source | 112,143,000Source | 120,445,000Source | 181,629,000Source | 129,692,000Source | 132,095,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,107,000Source | 1,531,000Source | 1,534,000Source | 989,000Source | 1,821,000Source | 1,483,000Source | 1,692,000Source | 2,168,000Source | 1,863,000Source | 2,149,000Source | 2,234,000Source | 4,344,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,792,000Source | 3,797,000Source | 1,977,000Source | 3,052,000Source | 3,976,000Source | 2,255,000Source | 3,306,000Source | 4,205,000Source | 2,527,000Source | 3,554,000Source | 4,429,000Source | 4,770,000Source |
| Other Assets, NoncurrentUSD | 1,647,000Source | 1,179,000Source | 1,179,000Source | 1,647,000Source | — | 1,510,000Source | 1,647,000Source | — | 1,653,000Source | 1,647,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 16,696,000Source | 17,792,000Source | 12,427,000Source | 15,546,000Source | 14,527,000Source | 12,317,000Source | 15,959,000Source | 12,542,000Source | 17,201,000Source | 19,802,000Source | 17,070,000Source | 10,751,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 31,000Source | 31,000Source | 42,000Source | 31,000Source | 31,000Source | 38,000Source | 31,000Source | 23,000Source | 31,000Source | 31,000Source | 23,000Source | 22,000Source |
| Additional Paid in CapitalUSD | 384,356,000Source | 370,224,000Source | 398,543,000Source | 380,562,000Source | 367,750,000Source | 389,396,000Source | 376,732,000Source | 240,932,000Source | 387,255,000Source | 373,284,000Source | 237,675,000Source | 226,580,000Source |
| Retained Earnings (Accumulated Deficit)USD | -255,896,000Source | -174,145,000Source | -311,887,000Source | -237,662,000Source | -151,704,000Source | -293,923,000Source | -216,656,000Source | -132,906,000Source | -274,881,000Source | -196,976,000Source | -116,420,000Source | -56,032,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 112,000Source | 782,000Source | -33,000Source | 106,000Source | -19,000Source | 4,000Source | 283,000Source | -70,000Source | 111,000Source | 447,000Source | -83,000Source | -95,000Source |
| Stockholders' Equity Attributable to ParentUSD | 128,603,000Source | 196,892,000Source | 86,665,000Source | 143,037,000Source | 216,058,000Source | 95,515,000Source | 160,390,000Source | 107,979,000Source | 112,516,000Source | 176,786,000Source | 121,195,000Source | 170,475,000Source |
| Liabilities and EquityUSD | 145,299,000Source | 214,684,000Source | 99,092,000Source | 158,583,000Source | 230,585,000Source | 107,832,000Source | 176,349,000Source | 120,521,000Source | 129,717,000Source | 196,588,000Source | 138,265,000Source | 181,226,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 14,891,000Source | 14,819,000Source | 11,447,000Source | 13,431,000Source | 11,284,000Source | 11,054,000Source | 13,550,000Source | 9,041,000Source | 15,664,000Source | 17,214,000Source | 13,303,000Source | 6,516,000Source |
| Operating Lease, Liability, CurrentUSD | 1,184,000Source | 1,040,000Source | 1,135,000Source | 1,148,000Source | 978,000Source | 1,152,000Source | 1,105,000Source | 944,000Source | 1,172,000Source | 1,057,000Source | 877,000Source | 726,000Source |
| Accounts Payable, CurrentUSD | 996,000Source | 1,506,000Source | 861,000Source | 1,163,000Source | 1,261,000Source | 1,162,000Source | 3,691,000Source | 2,056,000Source | 2,277,000Source | 758,000Source | 5,048,000Source | 904,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,805,000Source | 2,973,000Source | 980,000Source | 2,115,000Source | 3,243,000Source | 1,263,000Source | 2,409,000Source | 3,501,000Source | 1,537,000Source | 2,588,000Source | 3,767,000Source | 4,235,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,099,000Source | 1,272,000Source | 1,527,000Source | 1,785,000Source |
| Short-term InvestmentsUSD | 93,849,000Source | 144,038,000Source | 48,542,000Source | 95,528,000Source | 134,531,000Source | 63,673,000Source | 110,481,000Source | 85,368,000Source | 77,083,000Source | 139,662,000Source | 91,443,000Source | 98,232,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -19,042,000Source | -19,680,000Source | -77,905,000Source | -80,556,000Source | -60,388,000Source | -31,167,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,181,000Source | 3,791,000Source | 14,720,000Source | 14,288,000Source | 11,618,000Source | 2,185,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,202,000Source | 2,816,000Source | 1,536,000Source | -3,586,000Source | 3,609,000Source | -245,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -20,538,000Source | -19,535,000Source | -63,665,000Source | -65,669,000Source | -42,641,000Source | -30,117,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 13,127,000Source | 19,214,000Source | 66,100,000Source | -51,771,000Source | 50,717,000Source | -141,676,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 14,000Source | 58,000Source | 1,669,000Source | 2,768,000Source | 1,288,000Source | 2,166,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 33,000Source | 344,000Source | 750,000Source | 2,520,000Source | 1,297,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -33,000Source | -343,000Source | -749,000Source | 121,027,000Source | -1,554,000Source | 101,709,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -7,444,000Source | -664,000Source | 1,686,000Source | 3,587,000Source | 6,522,000Source | -70,084,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 35,607,000Source | 43,611,000Source | 41,612,000Source | 42,096,000Source | 34,258,000Source | 39,352,000Source | 41,702,000Source | 40,016,000Source | 36,429,000Source | 29,907,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,911,000Source | 3,671,000Source | 2,214,000Source | 3,927,000Source | 2,181,000Source | 3,791,000Source | 14,720,000Source | 14,288,000Source | 11,618,000Source | 2,185,000Source |
| DepreciationUSD | — | — | 300,000Source | 300,000Source | 400,000Source | 300,000Source | 383,000Source | 311,000Source | 1,356,000Source | 1,006,000Source | 536,000Source | 364,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | 200,000Source | -100,000Source | 100,000Source | — |
| General and Administrative ExpenseUSD | — | — | 6,039,000Source | 6,276,000Source | 4,824,000Source | 6,467,000Source | 4,736,000Source | 6,248,000Source | 24,124,000Source | 25,207,000Source | 21,079,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 7,000,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,234,000Source | -22,441,000Source | -17,964,000Source | -21,006,000Source | -19,042,000Source | -19,680,000Source | -77,905,000Source | -80,556,000Source | -60,388,000Source | -31,167,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,453,000Source | 2,699,000Source | 704,000Source | 1,643,000Source | 860,000Source | 1,982,000Source | 6,209,000Source | 8,643,000Source | — | 1,490,000Source |
| Operating ExpensesUSD | — | — | 19,687,000Source | 25,140,000Source | 18,668,000Source | 22,649,000Source | 19,902,000Source | 21,662,000Source | 84,114,000Source | 89,199,000Source | 67,103,000Source | 32,657,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -53,000Source | 1,000Source | -156,000Source | -87,000Source | -129,000Source | -14,000Source | -270,000Source | -558,000Source | 6,715,000Source | 1,490,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 1,000Source | 1,000Source | 90,000Source | 775,000Source | 24,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | -100,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -19,687,000Source | -25,140,000Source | -18,668,000Source | -22,649,000Source | -19,902,000Source | -21,662,000Source | -84,114,000Source | -89,199,000Source | -67,103,000Source | -32,657,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -53,000Source | 1,000Source | -156,000Source | -87,000Source | -129,000Source | -14,000Source | -270,000Source | -558,000Source | 6,715,000Source | 1,490,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -77,825,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,234,000Source | -22,441,000Source | -17,964,000Source | -21,006,000Source | -19,042,000Source | -19,680,000Source | -77,905,000Source | -80,556,000Source | -60,388,000Source | -31,167,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.47Source | -0.59Source | -0.43Source | -0.55Source | -0.49Source | -0.51Source | -2.02Source | -2.38Source | -2.74Source | -7.56Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.47Source | -0.59Source | -0.43Source | -0.55Source | -0.49Source | -0.51Source | -2.02Source | -2.38Source | -2.74Source | -7.56Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 38,560,464Source | 38,105,131Source | 41,841,887Source | 38,461,619Source | 38,724,803Source | 38,350,444Source | 38,509,281Source | 33,791,817Source | 22,078,190Source | 4,121,912Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 38,560,464Source | 38,105,131Source | 41,841,887Source | 38,461,619Source | 38,724,803Source | 38,350,444Source | 38,509,281Source | 33,791,817Source | 22,078,190Source | 4,121,912Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | 200,000Source | -100,000Source | 100,000Source | — |
| General and Administrative ExpenseUSD | — | — | 6,039,000Source | 6,276,000Source | 4,824,000Source | 6,467,000Source | 4,736,000Source | 6,248,000Source | 24,124,000Source | 25,207,000Source | 21,079,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -78,014,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 1,506,000Source | 2,698,000Source | 860,000Source | 1,730,000Source | 989,000Source | 1,996,000Source | 6,479,000Source | 9,201,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 7,000,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 1,453,000Source | 2,699,000Source | 704,000Source | 1,643,000Source | 860,000Source | 1,982,000Source | 6,209,000Source | 8,643,000Source | — | 1,490,000Source |
| Operating ExpensesUSD | — | — | 19,687,000Source | 25,140,000Source | 18,668,000Source | 22,649,000Source | 19,902,000Source | 21,662,000Source | 84,114,000Source | 89,199,000Source | 67,103,000Source | 32,657,000Source |
| Research and Development ExpenseUSD | — | — | 13,648,000Source | 18,864,000Source | 13,844,000Source | 16,182,000Source | 15,166,000Source | 15,414,000Source | 59,990,000Source | 63,992,000Source | 46,024,000Source | — |
Offerings
Registration 333-300095
Filing attachments
acrv-ex99_1.htm · 8-K · 2026-11-20
Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3, Gerald Falchook4, David Sommerhalder5, Benedito A. Carneiro6, Judy Wang7, Monica Mita8, Kamlesh K. Sankhala9, Jeffery Russell10, David Levitz11, Lu Gan12, Besiana P. Beqo12, Kristina Masson12, Christina A. Scherer12, Erick Gamelin12, Eric Devroe12, Peter Blume-Jensen12, Mansoor R. Mirza12, Nicole Nevadunsk…
Read attachment ↗d185923dex43.htm · S-3 · 2026-11-16
Exhibit 4.3 ACRIVON THERAPEUTICS, INC. INDENTURE Dated as of, 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. …
Read attachment ↗acrv-ex99_1.htm · 8-K · 2026-11-16
Exhibit 99.1 Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach AI-driven AP3 platform was used for profiling against approved JAK inhibitors to identify recently acquired ACR-525, a Phase 2-ready, potentially best-in-class, highly selective JAK1 inhibitor, and a differentiated preclinical PKCθ program Late-…
Read attachment ↗acrv-ex99_1.htm · 8-K · 2026-11-10
CORPORATE R&D AND KOL EVENT ACRIVON’S NEW I&I PROGRAMS DIFFERENTIATED ASSETS IDENTIFIED WITH PROPRIETARY AP3 PLATFORM NOVEMBER 10, 2026 Exhibit 99.1 Forward-looking statements Forward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future…
Read attachment ↗acrv-ex99_1.htm · 8-K · 2026-11-06
Exhibit 99.1 Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease As part of Acrivon’s due diligence, extensive AP3 profiling against approved JAK inhibitors and dupilumab revealed ACR-525 as a highly-selective, pot…
Read attachment ↗acrv-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 acrv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor types advancing in randomized dose expansion phase supported by a promising, favorable safety profile and durable single-agent cli…
Read attachment ↗